NO20073959L - Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller - Google Patents

Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller

Info

Publication number
NO20073959L
NO20073959L NO20073959A NO20073959A NO20073959L NO 20073959 L NO20073959 L NO 20073959L NO 20073959 A NO20073959 A NO 20073959A NO 20073959 A NO20073959 A NO 20073959A NO 20073959 L NO20073959 L NO 20073959L
Authority
NO
Norway
Prior art keywords
preparation
quinazoline derivative
cancer cell
cell growth
inhibiting cancer
Prior art date
Application number
NO20073959A
Other languages
English (en)
Inventor
Young Jin Ham
Ji Hyeon Gong
Mi Young Cha
Jong Woo Kim
Maeng Sup Kim
Eun Young Kim
Ji Yeon Song
Chang In Kim
Se Young Kim
Gwan Sun Lee
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of NO20073959L publication Critical patent/NO20073959L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Oppfinnelsen angår kinazolinderivat og et farmasøytisk akseptabelt salt derav for inhibering av vekst av cancerceller, en fremgangsmåte for fremstilling av kinazolinderivatet og et farmasøytisk preparat omfattende dette som en aktiv ingrediens.
NO20073959A 2004-12-29 2007-07-27 Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller NO20073959L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20040114839 2004-12-29
KR1020050111724A KR100735639B1 (ko) 2004-12-29 2005-11-22 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
PCT/KR2005/004395 WO2006071017A1 (en) 2004-12-29 2005-12-20 Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof

Publications (1)

Publication Number Publication Date
NO20073959L true NO20073959L (no) 2007-09-27

Family

ID=36615106

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073959A NO20073959L (no) 2004-12-29 2007-07-27 Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller

Country Status (15)

Country Link
US (1) US8003658B2 (no)
EP (1) EP1844022B1 (no)
JP (1) JP4914372B2 (no)
KR (2) KR100735639B1 (no)
CN (1) CN101094840B (no)
AU (1) AU2005320472B2 (no)
BR (1) BRPI0519474A2 (no)
CA (1) CA2592286C (no)
ES (1) ES2427445T3 (no)
IL (1) IL183583A (no)
MX (1) MX2007007458A (no)
NO (1) NO20073959L (no)
NZ (1) NZ556773A (no)
RU (1) RU2362773C2 (no)
WO (1) WO2006071017A1 (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
KR101028952B1 (ko) 2003-08-14 2011-04-12 어레이 바이오파마 인크. 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
JP2008542356A (ja) * 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク 異常な細胞増殖の治療用の二環式誘導体
CA2755268C (en) 2005-11-15 2013-12-31 Array Biopharma, Inc. Erbb inhibitors
CN101003514A (zh) * 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
KR100929146B1 (ko) * 2006-06-28 2009-12-01 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체
JP2010502743A (ja) * 2006-09-11 2010-01-28 キュリス，インコーポレイテッド 抗増殖薬剤としての多機能性低分子
MX2009002585A (es) * 2006-09-11 2009-08-24 Curis Inc Inhibidores e egfr a base de quinolina que contienen porcion de enlace de zinc.
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
CN101245050A (zh) * 2007-02-14 2008-08-20 上海艾力斯医药科技有限公司 4-苯胺喹唑啉衍生物的盐
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
US8148532B2 (en) * 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
US20120065201A1 (en) * 2007-03-28 2012-03-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20120101113A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
PT2154967E (pt) 2007-04-16 2014-06-05 Hutchison Medipharma Entpr Ltd Derivados de pirimidina
KR101397523B1 (ko) * 2007-04-27 2014-05-30 한미약품 주식회사 다중저해제로서의 퀴나졸린 유도체
CN101348466B (zh) * 2007-07-20 2012-06-20 江苏艾力斯生物医药有限公司 N-{4-[3-氯-4-(3-氟-苄氧基)-苯胺基]-喹唑啉-6-基}-丙烯酰胺的制备方法
CN101357905B (zh) * 2007-08-01 2012-06-20 江苏艾力斯生物医药有限公司 4-[3-氯-4-(3-氟-苄氧基)-苯胺基]-6-取代胺基-喹唑啉衍生物的制备方法
CN101544609A (zh) * 2008-03-25 2009-09-30 上海艾力斯医药科技有限公司 4-苯胺喹唑啉衍生物的结晶形式
US7829574B2 (en) 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
CN101584696A (zh) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
US8426430B2 (en) * 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
US7737157B2 (en) 2008-08-29 2010-06-15 Hutchison Medipharma Enterprises Limited Pyrimidine compounds
ITMI20082336A1 (it) * 2008-12-29 2010-06-30 Univ Parma Composti inibitori irreversibili di egfr con attivita' antiproliferativa
US8575203B2 (en) 2010-04-21 2013-11-05 Boehringer Ingelheim International Gmbh Chemical compounds
CA2800913C (en) 2010-06-03 2019-07-23 Pharmacyclics, Inc. The use of inhibitors of bruton's tyrosine kinase (btk)
CN102311438A (zh) * 2010-06-30 2012-01-11 和记黄埔医药（上海）有限公司 喹唑啉化合物
CN102906086B (zh) * 2010-06-30 2014-02-12 和记黄埔医药（上海）有限公司 喹唑啉化合物
CN102485735B (zh) * 2010-12-02 2014-09-24 东莞南方医大代谢医学研发有限公司 6-果糖氨-4-芳胺基喹唑啉衍生物及其用途
US9138436B2 (en) 2011-07-13 2015-09-22 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
JP6437820B2 (ja) 2011-07-27 2018-12-12 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド キナゾリン誘導体、その製造方法、中間体、組成物及びその適用
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
WO2013143057A1 (zh) * 2012-03-26 2013-10-03 中国科学院福建物质结构研究所 喹唑啉衍生物及用途
CN103360382B (zh) * 2012-03-26 2016-04-27 中国科学院福建物质结构研究所 喹唑啉衍生物及其用途
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
CN103102315B (zh) * 2012-11-01 2016-01-20 云南大学 一种喹唑啉类芳基脲及其制备方法和用途
CN102942561A (zh) * 2012-11-06 2013-02-27 深圳海王药业有限公司 4-氨基喹唑啉杂环化合物及其用途
CN103275018B (zh) * 2013-04-26 2016-03-02 浙江工业大学 4-[3-氯-4-取代苯胺基]-6-取代甲酰氨基喹唑啉类化合物及制备和应用
CN103288758B (zh) * 2013-05-16 2015-01-21 苏州明锐医药科技有限公司 一种达克米替尼的制备方法
CA2925124A1 (en) 2013-09-30 2015-04-02 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
CN103570692A (zh) * 2013-10-31 2014-02-12 浙江大学 含吖丙啶环侧链的喹唑啉衍生物及制备和应用
WO2015120821A1 (zh) * 2014-02-17 2015-08-20 江苏恩华络康药物研发有限公司 一类水溶性丙泊酚衍生物及其用途
US10239851B2 (en) 2014-02-17 2019-03-26 Qingeng Li Carboxylic acid derivatives and use thereof in the preparation of prodrugs
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
KR102139496B1 (ko) 2014-12-15 2020-07-30 더 리젠츠 오브 더 유니버시티 오브 미시간 Egfr 및 pi3k의 소분자 억제제
CN106117182B (zh) * 2016-06-20 2019-08-30 中国药科大学 喹唑啉-n-苯乙基四氢异喹啉类化合物及其制备方法和应用
JP2020023441A (ja) * 2016-11-02 2020-02-13 国立大学法人九州大学 Ｅｇｆｒ阻害及び腫瘍治療に有用な新規化合物
AU2019340598A1 (en) * 2018-09-14 2021-03-18 Hanmi Pharmaceutical Co., Ltd. Crystalline forms of a quinazole compound and its hydrochloride salts
CN117295716A (zh) 2020-12-22 2023-12-26 麦克尼斯迪克治疗有限公司 作为egfr和/或pi3k抑制剂的取代氨基苄基杂芳基化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
SI20582A (sl) * 2000-05-05 2001-12-31 Univerza V Ljubljani Novi inhibitorji trombina, njihova priprava in uporaba
OA12291A (en) 2000-06-22 2004-03-18 Pfizer Prod Inc Substituted bicyclic derivatives for the treatmentof abnormal cell growth.
US20020082270A1 (en) * 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
WO2002068396A1 (en) * 2001-02-26 2002-09-06 Mcgill University Combi-molecules having signal transduction inhibitory properties and dna damaging properties
PE20040945A1 (es) * 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
ES2374553T3 (es) 2004-05-06 2012-02-17 Warner-Lambert Company Llc 4-fenilamino-quinazolin-6-il-amidas.

Also Published As

Publication number Publication date
NZ556773A (en) 2010-10-29
KR100658891B1 (ko) 2006-12-15
EP1844022A1 (en) 2007-10-17
MX2007007458A (es) 2007-08-15
CN101094840A (zh) 2007-12-26
RU2362773C2 (ru) 2009-07-27
WO2006071017A1 (en) 2006-07-06
EP1844022B1 (en) 2013-08-14
KR100735639B1 (ko) 2007-07-04
CN101094840B (zh) 2012-10-31
BRPI0519474A2 (pt) 2009-01-27
AU2005320472B2 (en) 2009-02-26
IL183583A (en) 2015-11-30
JP2008525522A (ja) 2008-07-17
IL183583A0 (en) 2007-09-20
US20080009509A1 (en) 2008-01-10
CA2592286A1 (en) 2006-07-06
ES2427445T3 (es) 2013-10-30
KR20060076186A (ko) 2006-07-04
RU2007128920A (ru) 2009-02-10
JP4914372B2 (ja) 2012-04-11
KR20060076210A (ko) 2006-07-04
AU2005320472A1 (en) 2006-07-06
EP1844022A4 (en) 2009-10-28
CA2592286C (en) 2012-05-29
US8003658B2 (en) 2011-08-23

Similar Documents

Publication Publication Date Title
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
TW200833693A (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
IS8132A (is) Pýrósóló-kínasólín afleiður, aðferð við framleiðslu þeirra og notkun sem kínasa hindrar
WO2005005414A3 (en) Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AU2003244632A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AU2003227741A1 (en) Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
BRPI0415288A (pt) composto, composição farmacêutica, método para tratar ou prevenir doenças, e, método para preparar o composto
BRPI0413427A (pt) derivados de piridilpirrol ativos como inibidores da cinase
RS52169B (en) STABLE LAKVINIMOD PREPARATIONS
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
WO2008150118A3 (en) Novel amide derivative for inhibiting the growth of cancer cells
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
AU2003244649A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2005014572A8 (en) Pyrimidylpyrrole derivatives active as kinase inhibitors
WO2009032843A3 (en) Deuterated ethambutols and their use
UA102219C2 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы
EA201000889A1 (ru) Тризамещенные пиперидины в качестве ингибиторов ренина
WO2007052167A3 (en) Stable composition for a pharmaceutical formulation containing olanzapine
CU23596A3 (es) Derivados de pirazol-quinazolina y proceso para su preparación

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: TANDBERGS PATENTKONTOR AS, POSTBOKS

RE Reestablishment of rights (par. 72 patents act)